logo

RNA

Avidity Biosciences·NASDAQ
--
--(--)
--
--(--)
4.58 / 10
Netural

Fundamental metrics indicate modest status (4.6/10). Bullish considerations: Revenue-MV and Profit-MV, while concerns exist in Current assets turnover ratio and Fixed assets turnover ratio. Final rating: cautious.

Fundamental(4.58)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-3.84
Score2/3
Weight17.38%
1M Return11.69%
Inventory turnover ratio
Value47.85
Score3/3
Weight6.69%
1M Return5.26%
Gross profit margin (%)
Value100.00
Score3/3
Weight15.31%
1M Return10.80%
Profit-MV
Value0.46
Score2/3
Weight11.40%
1M Return7.79%
PB-ROE
Value1.41
Score2/3
Weight16.01%
1M Return10.68%
Current assets turnover ratio
Value0.01
Score0/3
Weight-2.09%
1M Return-1.88%
Fixed assets turnover ratio
Value1.05
Score1/3
Weight-1.81%
1M Return-1.64%
Asset-MV
Value-0.50
Score2/3
Weight26.02%
1M Return15.13%
Cash-MV
Value-0.07
Score2/3
Weight11.42%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.34%
1M Return-0.30%
Is RNA fundamentally strong?
  • RNA scores 4.58/10 on fundamentals and holds a Fair valuation at present. Backed by its -27.03% ROE, -2634.59% net margin, -24.75 P/E ratio, 5.98 P/B ratio, and -45.49% earnings growth, these metrics solidify its Netural investment rating.